Chronic Nitrofurantoin-Induced Lung Disease

Mendez, Jose L.; Nadrous, Hassan F.; Hartman, Thomas E.; Ryu, Jay H.
October 2005
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1298
Academic Journal
OBJECTIVE: To reassess the clinical and radiological features of chronic nitrofurantoin-induced lung disease and eventual clinical outcome. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 18 patients with chronic nitrofurantoin-induced lung disease who were seen at the Mayo Clinic in Rochester, Minn. from January 1, 1997, to December 31, 2002. RESULTS: The median age of the 18 patients was 72 years (range, 47–90 years) at the time of diagnosis; 17 (94%) were women. Onset of symptoms occurred after a median interval of 23 months (range, 10–144 months) following the initiation of nitrofurantoin therapy for the prevention of recurrent urinary tract infections. All patients presented with persistent dyspnea and cough associated with lung infiltrates detected on chest radiography. Ten computed tomograms were available for review and revealed bilateral areas of ground-glass opacities in all cases and showed sub-pleural irregular linear opacities and patchy consolidation in some cases. Nitrofurantoin therapy was discontinued in all patients, and most improved subsequently; 9 patients received corticosteroid therapy. CONCLUSIONS: Chronic nitrofurantoin-induced lung disease is seen predominantly in older women who present with respiratory symptoms after a year or more of nitrofurantoin therapy. Associated radiological features are relatively nonspecific but usually include bilateral areas of ground-glass opacities on computed tomography of the chest. Cessation of nitrofurantoin therapy leads to improvement and suffices in the management of some patients, although corticosteroid therapy may be helpful in those more severely affected.


Related Articles

  • Sodium polystyrene sulfonate.  // Reactions Weekly;6/1/2013, Issue 1455, p31 

    The article describes the case of a 55-year-old man who developed pulmonary disease, and later died, following aspiration of sodium polystyrene sulfonate.

  • Lenalidomide.  // Reactions Weekly;9/15/2012, Issue 1419, p32 

    The article describes the case of a 75-year-old man who developed pulmonary zygomycosis while receiving lenalidomide for the treatment of myelodysplast syndrome.

  • Gemcitabine.  // Reactions Weekly;1/14/2012, Issue 1384, p28 

    The article describes six cases of interstitial lung disease (ILD) which developed while patients were receiving treatment with gemcitabine for non-small-cell lung cancer or pancreatic cancer.

  • Sever Allergic Pneumonitis from Hydrochlorothiazide. Beaudry, Claude // Annals of Internal Medicine;Feb73, Vol. 78 Issue 2, p251 

    Presents a study which examined hydrochlorothiazide-induced pulmonary allergic pneumonitis. Background on the medical history of patients involved in the study; Overview of previous studies on the side effects of thiazide therapy; Discussion on allergic manifestations in the lungs.

  • Search for late-onset side effects of practolol. Barclay, J.; Ramsay, L.E.; Jay, J.L.; McQueen, A.; Lorimer, A.R. // British Medical Journal;8/19/1978, Vol. 2 Issue 6136, p538 

    Examines the side effects of practolol on patients with pulmonary complications in Glasgow, Scotland. Documentation of oculomucocutaneous syndrome; Exposure of patients to practolol toxicity; Sensitivity of intercellular antibody on toxicity index.

  • Ibritumomab tiuxetan Y-90/rituximab.  // Reactions Weekly;3/31/2012, Issue 1395, p24 

    The article describes the case of a 30-year-old woman who developed interstitial lung disease following ibritumomab tiuxetan Y-90 andrituximab therapy for relapsed diffuse large B cell lymphoma.

  • DRUG POINTS. Rademaker, J.; Severs, M.; Bewley, A.P.; Feher, M.D.; Staughton, R.C.D.; Woolfrey, S.; Gammack, N.S.; Dewar, M.S.; Brown, P.J.E.; Tidswell, P.; d'Assis-Fonseca, A. // BMJ: British Medical Journal (International Edition);7/24/93, Vol. 307 Issue 6898, p241 

    Examines the side effects of several drugs in Great Britain. Incidence of opiate toxicity among elderly patients with chronic lung disease; Effects of fluoxetine and warfarin interaction; Contribution of terfenadine in the existence of generalized seizure.

  • Dronedarone.  // Reactions Weekly;9/8/2012, Issue 1418, p23 

    The article describes the case of a 73-year-old man who developed interstitial lung disease after receiving dronedarone.

  • Erlotinib.  // Reactions Weekly;1/5/2013, Issue 1433, p20 

    The article describes the case of a 68-year-old woman who developed interstitial lung disease (ILD) while receiving erlotinib for the treatment of lung adenocarcinoma.

  • Rituximab.  // Reactions Weekly;1/18/2014, Issue 1484, p31 

    The article presents a case study of a 66-year-old woman who had developed interstitial lung disease due to rituximab therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics